Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Monoclonal antibodies in gastrointestinal cancers.

Bronte G, Cicero G, Cusenza S, Galvano A, Musso E, Rizzo S, Sortino G, Roselli M, Bazan V, Fiorentino E, Russo A.

Expert Opin Biol Ther. 2013 Jun;13(6):889-900. doi: 10.1517/14712598.2013.774367. Epub 2013 Feb 27. Review.

PMID:
23441760
2.

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.

Winder T, Lenz HJ.

Gastroenterology. 2010 Jun;138(6):2163-76. doi: 10.1053/j.gastro.2010.02.005. Review.

PMID:
20420953
3.

Changing pathology with changing drugs: tumors of the gastrointestinal tract.

Cervera P, Fléjou JF.

Pathobiology. 2011;78(2):76-89. doi: 10.1159/000315535. Epub 2011 Jun 15. Review.

4.

Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.

Geva R, Prenen H, Topal B, Aerts R, Vannoote J, Van Cutsem E.

J Surg Oncol. 2010 Dec 15;102(8):937-45. doi: 10.1002/jso.21760. Review.

PMID:
21165996
5.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
6.

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.

Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A.

Curr Drug Metab. 2011 Dec;12(10):944-55. Review.

PMID:
21787268
7.

Current issues in the targeted therapy of advanced colorectal cancer.

Knijn N, Tol J, Punt CJ.

Discov Med. 2010 Apr;9(47):328-36. Review.

8.

Pharmacogenetics of EGFR and VEGF inhibition.

Pander J, Gelderblom H, Guchelaar HJ.

Drug Discov Today. 2007 Dec;12(23-24):1054-60. Epub 2007 Nov 26. Review.

PMID:
18061885
9.
10.

Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.

Italiano A.

Oncology. 2006;70(3):161-7. Epub 2006 May 3. Review.

PMID:
16675911
11.

Molecular mechanisms and targeting of colorectal cancer.

Vanhoefer U.

Semin Oncol. 2005 Dec;32(6 Suppl 8):7-10. Review.

PMID:
16360005
12.

Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.

McIntire M, Redston M.

Arch Pathol Lab Med. 2012 May;136(5):496-503. doi: 10.5858/arpa.2011-0167-RA. Epub 2012 Jan 9. Review.

PMID:
22229849
13.

Targeted therapy in colorectal cancer.

Rajpal S, Venook AP.

Clin Adv Hematol Oncol. 2006 Feb;4(2):124-32. Review.

PMID:
16728921
14.
15.

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.

Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV.

Curr Opin Oncol. 2005 May;17(3):212-7. Review.

PMID:
15818163
17.

Monoclonal antibodies for targeted therapy in colorectal cancer.

Banerjee S, Flores-Rozas H.

Cancer Biol Ther. 2010 Apr 15;9(8):563-71. Epub 2010 Apr 4. Review.

PMID:
20200482
18.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
19.

Molecular predictors of response to chemotherapy in colorectal cancer.

Dienstmann R, Vilar E, Tabernero J.

Cancer J. 2011 Mar-Apr;17(2):114-26. doi: 10.1097/PPO.0b013e318212f844. Review.

PMID:
21427555
20.

The future of anti-EGFR therapy.

D'Andrea MR, Gasparini G.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S88-93. Review.

PMID:
17520586

Supplemental Content

Support Center